Roche Receives CE Mark for New Blood Test to Detect Alzheimer's Pathology: Elecsys Plasma Phosphorylated-tau 217
May 13, 2026
May 13, 2026
BASEL, Switzerland, May 13 -- Roche, a biotech company, issued the following news release on May 12, 2026:
* * *
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys(R) plasma phosphorylated-tau 217 (pTau217)
* Elecsys(R) pTau217 is the first blood test for Alzheimer's disease pathology with a single assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster dia . . .
* * *
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys(R) plasma phosphorylated-tau 217 (pTau217)
* Elecsys(R) pTau217 is the first blood test for Alzheimer's disease pathology with a single assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster dia . . .